ReviewAnnals of clinical microbiology and antimicrobials2020
SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.
Review in Annals of clinical microbiology and antimicrobials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Complication and Sequelae of COVID-19: What Should We Pay Attention to in the Post-Epidemic Era.Frontiers in immunology · 2021Pooled it
- How people evaluate anti-corona measures II-Lessons for future crises from a longitudinal study and qualitative analysis.Frontiers in psychology · 2026Article
- Emerging zoonotic threats: HKU5-CoV-2 and the CBRNE approach to pandemic prevention.Infectious diseases & immunity · 2026Review
- Association of HLA-B gene polymorphism and blood groups with COVID-19 susceptibility and severity.Scientific reports · 2025Article
- Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study.Bioresources and bioprocessing · 2024Article
- Healthcare professionals' acceptance of COVID-19 vaccination for their children: A cross-sectional study at a tertiary care hospital in Western India.Health science reports · 2024Article
- Global lineage evolution pattern of sars-cov-2 in Africa, America, Europe, and Asia: A comparative analysis of variant clusters and their relevance across continents.Journal of translational internal medicine · 2023Article
- Leukopenia and leukocytosis as strong predictors of COVID-19 severity: A cross-sectional study of the hematologic abnormalities and COVID-19 severity in hospitalized patients.Health science reports · 2023Article
- Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model.BMC microbiology · 2023Article
- COVID-19 in the Arab countries: Three-year study.F1000Research · 2023Review
- Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.Journal of infection and public health · 2023Review
- Network pharmacology and bioinformatics analysis identifies potential therapeutic targets ofFrontiers in endocrinology · 2023Article
- Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory.Human vaccines & immunotherapeutics · 2022Review
- Risk Factors for COVID-19 Mortality in Malaysia.The Malaysian journal of medical sciences : MJMS · 2022Article
- A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.Narra J · 2022Review
- Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess.Human vaccines & immunotherapeutics · 2022Article
- A Cross-Sectional, Questionnaire-Based Survey on Air Infection Control among Romanian People.International journal of environmental research and public health · 2022Article
- Teachers' Response to Stress, Anxiety and Depression During COVID-19 Lockdown: What Have We Learned From the Pandemic?The Journal of school health · 2022Article
- Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study.Microbial pathogenesis · 2022Article
- Conventional and Microfluidic Methods for the Detection of Nucleic Acid of SARS-CoV-2.Micromachines · 2022Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.